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Background: Pharmacist intervention in improving patient adherence to antidepressants is 
coupled with better outcomes.
Aims: The aim of this investigation was to systematically examine the published literature 
to explore different types of pharmacist interventions used for enhancing patient adherence 
to antidepressant medications. Three specific questions guided the review: what is the impact 
of pharmacist interventions on adherence to antidepressant medication? What is the impact of 
pharmacist interventions on patient-reported outcomes and patient satisfactions? What are the 
types of interventions used by pharmacists to enhance patients’ adherence to antidepressants? 
Search strategies: A systematic review of the literature was conducted during August– 
November 2010 using PubMed, BIOSIS Previews® Web of Science, ScienceDirect, the Cochrane 
Library, PsycINFO®, IngentaConnect™, Cambridge Journals Online, and Medscape databases. 
Key text words and medical subject headings included pharmacist intervention, medication 
intervention, depression, medication adherence, health-related quality of life, patient-reported 
outcomes, and antidepressants.
Results: A total of 119 peer-reviewed papers were retrieved; 94 were excluded on the basis of 
abstract review and 13 after full-text analysis, resulting in twelve studies suitable for inclusion 
and intensive review. The most common intervention strategy that pharmacists utilized was a 
combination of patient education and drug monitoring. A cumulative patient adherence improve-
ment in this review ranged from 15% to 27% attributed to utilization of different interventions 
and different combinations of interventions together with patient satisfaction with the treatment 
when depression improved.
Conclusion: This review suggests that pharmacist intervention is effective in the improve-
ment of patient adherence to antidepressants. This may be a basis for more studies examining 
the effectiveness of innovative interventions by pharmacists to enhance patient adherence to 
antidepressant medications.
Keywords: pharmacist interventions, adherence to medication, depression, antidepressants, 
systematic review
Introduction
Depressive illness is a public health issue of major significance. Lifetime prevalence 
is estimated at about 15% and most depressed patients are treated in general practice.1 
Despite the proven efficacy of antidepressant medication, many depressed patients do 
not receive an adequate dosage and duration of treatment.2 Shortcomings in treatment 
for depression are frequently noted both in primary care and specialized settings. 
The effectiveness of antidepressants is also reduced by patients’ non-adherence. 
Observational studies found discontinuation rates of 28% at 1 month and 44% to 52% 
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at 3 months.3 Non-adherence may result in serious conse-
quences such as treatment failure, relapse, a chronic course 
of depression, complications, high medical care utilization, 
increased costs, and impairment in work functioning and 
other activities.3
The role of pharmacists in the medical field has recently 
grown well beyond the dispensing function and expanded to 
clinical trials, health economics, patient education, and other 
related roles.4 Pharmacist interventions have proved to be 
beneficial for improving treatment outcomes in a variety of 
healthcare settings.5 Because of their excellent position of 
having direct patient contact, pharmacists can help patients 
to address barriers to adherence which may include, inter 
alia, concerns about adverse effects, increased duration of 
therapy, frequency of drug administration, cost-effectiveness, 
and pill burden; they incorporate interventions into the care 
of their patients with the use of different strategies such as 
patient education, drug monitoring, and management of 
adverse reactions.
Aims
The aim of this investigation was to systematically examine 
the published literature to explore different types of pharma-
cist interventions used in order to enhance patients’ adherence 
to antidepressant medication. Three specific questions guided 
the review:
1.  What is the impact of pharmacist interventions on 
adherence to antidepressant medication?
2.  What is the impact of pharmacist interventions on patient-
reported outcomes and patient satisfaction?
3.  What are the types of interventions used by pharmacists 
to enhance patients’ adherence to antidepressants?
Methods
A systematic review of the published literature was conducted 
to identify all studies that had examined pharmacist 
interventions to improve adherence to antidepressant 
medication published from 2000–2010. The reasons for 
selecting this cutoff period were: most studies focusing on 
pharmacists’ interventions in patients with depression were 
conducted during this period; the role of pharmacists began 
to change and expand from just dispensing and compounding 
drugs to providing pharmaceutical care in the late 1990s and 
include reviewing of prescribed drugs, taking part in clinical 
rounds, becoming an important member of the clinical team, 
counseling in outpatient and inpatient settings, and others.6–8 
These papers were analyzed in line with qualitative review 
methodology to produce a number of data themes that were 
later grouped together to produce the dominant categories. In 
addition, the quality of the studies was assessed using the 
Jadad scale,9 which is easy to use, contains many of the 
important elements that have empirically been shown to 
correlate with bias, has known reliability and external validity, 
and is most widely used worldwide for such assessments.10 
The Jadad scale is a three-item scale that considers three 
features of a study: randomization, double-blinding, and flow 
of patients. Adequate description of allocation concealment 
was also evaluated. Total summed scores ranged from 0 to 7, 
with the higher scores indicating higher quality.11 However, 
blinding of pharmacists and participants was not possible 
because of the type of intervention assessed in this systematic 
review; therefore, total scores ranged from 0 to 5 (Table 1). 
Although the Jadad scale is a little out of date, it nonetheless 
still has all the statistical qualities and practical applications 
for assessing the quality of current randomized clinical 
Table 1 Quality of studies using the Jadad scale for reporting randomized controlled trials
Studies Adequate  
description  
of allocation  
concealment
Flow of patients  
is described  
and adequate
Flow of  
patients is  
described
Method of  
blinding is  
appropriate
Blinding is 
mentioned
Method of  
randomization  
is appropriate
Randomization  
is mentioned
Total
Canales13 0 1 1 0 0 0 1 3
Bultman14 1 0 1 0 0 0 1 3
Finley15 0 1 1 0 0 0 1 3
Finley16 0 1 1 0 0 1 1 4
Adler17 1 1 1 0 0 1 1 5
Capoccia18 0 0 1 0 0 0 1 2
Rickles19 1 1 1 0 0 1 1 5
Brook20 0 1 1 0 0 0 1 3
Al-Saffar21 0 1 1 0 0 1 1 4
Crockett22 0 0 1 0 0 0 1 2
Rickles23 1 1 1 0 0 1 1 5
Bosmans24 1 1 1 0 0 0 1 4
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trials.12 In light of the more elaborate scales that are emerging, 
whether or not the use of the Jadad scale is a weakness or 
strength of this research is a moot point.12
Information sources and searches
During August to November 2010, the following databases 
were searched for articles published between 2000 and 2010: 
PubMed, BIOSIS Previews, Web of Science, ScienceDirect, 
The Cochrane Library, PsycINFO, IngentaConnect, 
Cambridge Journals Online, and Medscape databases. 
A variety of key medical subject headings terms and text words 
were constructed for use within the databases: pharmacist 
intervention, medication intervention, depression, medication 
adherence, compliance, health-related quality of life, and 
patient-reported outcomes. The key words “pharmacist 
intervention” were then combined with “medication 
adherence”, “antidepressant medications”, “depression”, 
“health quality”, “patient-reported outcomes”, “randomized 
clinical trials”, “systematic reviews”, and “quality reports” for 
the purpose of the second round of the computer search.
Notably, “adherence”, “compliance”, and “persistence” 
have different meanings when used stringently. Adherence 
to medication is defined as: “the extent to which a person’s 
behavior, taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed 
recommendations from a health-care provider”.25 The term 
“adherence” rather than “compliance” is now advocated 
because compliance implies that the instructions of the 
health-care provider have to be followed in a passive way 
and that the patient is not expected to engage in a therapeutic 
association or any agreement with the healthcare provider.26 
On the other hand, persistence is described as continuous 
refilling of prescriptions in accordance with the suggested 
duration of the therapy, which is determined by evaluating 
solely whether or not the patient continues treatment.27 
In general, pharmacists’ interventions usually focus on 
medication; consequently, adherence is the primary outcome 
in most of these studies. For this particular reason, the two 
reviewers decided to focus on medication adherence rather 
than compliance or persistence in this systematic review.
Study selection
The titles and abstracts of all articles were scanned for ran-
domized control studies that had investigated the impact of 
pharmacists’ intervention on patient adherence to antidepres-
sant medication published from 2000 to 2010. The abstracts 
and studies were screened then discarded if they did not fit 
the selection criteria (Table 2). Studies that were identified as 
potentially relevant were retrieved where possible and further 
screened for relevance. A total of 119 papers were retrieved, 
with 94 excluded on the basis of abstract review and 13 after 
full-text analysis, resulting in the retention of 12 studies suit-
able for inclusion. The papers were analyzed qualitatively by 
applying the Jadad scale. The methodology for research that 
had been adopted in papers included in this review was that 
of randomized controlled trials. This is because randomized 
controlled trials are considered to be the optimal study design 
for minimizing bias and providing the most accurate estimate 
of complex interventions in terms of benefits; also, it is the 
only trial design to establish causal effects.28
Inclusion criteria
The considered inclusion criteria were as follows: published 
in English language; study is primary in nature; published in a 
peer-reviewed journal; full-text articles and publication dates 
match the years lying between 2000 to 2010; study design a 
randomized control study; recruited to investigate depressed 
adult patients, and the main outcome finding adherence to 
antidepressant medications.
Exclusion criteria
Studies without control groups or randomization, descriptive 
studies, pilot studies, results of postal surveys, and qualita-
tive interviews were excluded from this review. Non-English 
papers were also discarded to prevent cultural and linguistic 
bias in translation. Studies were also excluded if the pharma-
cist was not involved in the intervention or service provided 
to patients. In addition, papers were excluded if no partici-
pants in the sample were diagnosed with depression. Other 
exclusion criteria were depressed adolescent patients, edi-
torials, book chapters and duplicate articles, and systematic 
reviews, and if the focus of the study was not on adherence. 
Each study meeting the inclusion and exclusion criteria was 
sorted on the basis of the pharmacist intervention, sample 
size, follow-up, outcome measures, findings, country of 
origin, setting, and number of involved pharmacists.
Data abstraction
A grid was created to record the summaries of the articles 
for further conceptualization of the literature and later 
construction of the literature review. PICOS (participants, 
interventions, comparisons, outcomes, and study design) 
was used for data extraction. This initial tabulation 
presented information about the study characteristics, 
including the year of the study, the number of participants, 
type of intervention, comparison, country, research design, 
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Table 2 Summary of studies included in this review, 2000–2010
Study Methodology Study location Sample size Brief description of study aims
Canales13 Carried out in two phases.  
Control and experimental groups
Texas, USA 93 To determine the effects of a psychiatric 
pharmacist on clinical outcomes  
of acute care psychiatric inpatients.  
and to monitor hospitalization costs
Bultman14 Systematic, random sample of pharmacies  
and field study, interviewed patients
wisconsin, USA 100 To examine the effects of pharmacist  
monitoring on patient satisfaction and  
adherence to antidepressant  
medication therapy
Finley15 Pharmacist follow-up of patients for  
6 months through a combination of  
scheduled office visits and telephone calls.  
working closely with psychiatric liaisons
California, USA 220 To examine efforts to improve patient  
adherence to antidepressant drug  
therapy and outcomes
Finley16 A randomized controlled trial comparing  
the outcomes of subjects treated in care  
model intervention with subjects  
receiving usual care
California, USA 150 To measure the effects of a collaborative 
care model that emphasized the role  
of clinical pharmacists in providing drug  
therapy management and treatment  
follow-up to patients with depression
Adler17 A randomized clinical trial of a pharmacist  
intervention for depressed patients  
reporting antidepressant use and  
depression severity outcomes at 6 months
Massachusetts, USA 533 To evaluate outcomes of a pharmacist 
intervention for depressed patients  
in primary care
Capoccia18 Randomized to enhanced care or  
usual care for 1 year
washington, USA 74 To evaluate the impact of pharmacist 
interventions in collaborative care to 
improve the care of and outcomes  
for patients with depression, to test  
the effectiveness of pharmacist  
interventions in the collaboration model
Rickles19 Randomized, controlled unblended,  
mixed experimental design
wisconsin, USA 63 To explore the impact of telephone-
based education and monitoring by  
community pharmacists on multiple  
outcomes of pharmacist–patient  
collaboration
Brook20 Randomized controlled trial with  
6-month follow-up
The Netherlands 147 To improve adherence to antidepressant 
regimens through pharmacist  
intervention
Crockett22 Parallel-groups design with a control  
and intervention group
New South wales,  
Australia
106 Documentation and evaluation of  
patient outcomes into the role of  
rural community pharmacists in  
the management of depression
Rickles23 Randomized controlled, experimental  
design
wisconsin, USA 60 To determine whether or not telephone 
follow-up can influence the nature  
and extent to which antidepressant 
users provide feedback to pharmacists, 
whether patient characteristics are 
associated with the extent of patient 
feedback, how patient feedback affects 
subsequent outcomes after controlling 
for patient characteristics
Bosmans24 An economic evaluation performed  
alongside a 6-month randomized  
controlled trial
The Netherlands 88 To evaluate the cost-effectiveness of a 
pharmacy-based intervention to improve 
adherence to antidepressant therapy 
in adult patients receiving treatment in 
primary care
Al-Saffar21 Randomized into a control and two  
treatment groups. Treatment groups  
additionally received a patient information  
leaflet. Adherence was monitored  
at 2 and 5 months
Kuwait 270 To assess the acceptability and 
effectiveness of two educational 
initiatives on patterns of antidepressant 
medication use among depressed 
Kuwaiti patients
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outcomes, and a brief description of study aims. For the 
main analysis, data from the findings of these original stud-
ies were summarized into a model to display the themes 
that presented the type of   pharmacist intervention, patients’ 
outcome measures, and change in adherence rate. Data 
from each study were extracted and checked independently 
by the two reviewers. Any point of inconsistency was 
discussed between the two investigators in order to reach 
100% agreement regarding data abstracted from the 
selected studies.
Results
The search yielded 119 citations. Of these, 94 studies were 
excluded after review of the title and abstract (Figure 1). Of 
the remaining 25 studies, 13 studies were excluded because 
they did not meet the inclusion criteria for method design, 
or the intervention was conducted by non pharmacists, or 
focused on other patient groups. Twelve studies met the 
  criteria for inclusion in this review and were, therefore, 
selected for analysis. This section summarizes the results 
of the 12 core studies, which investigated pharmacists’ 
intervention to enhance patients’ adherence to antidepressant 
medication and related patient outcomes. A summary 
of findings from these peer-reviewed papers is shown in 
Tables 2–6. The 12 included studies published between 
2000 and 2010 were carried out in the USA, Canada, the 
Netherlands, Australia, and Kuwait.
Quality of included studies
Twelve studies met the criteria for inclusion in this review and 
were therefore selected for analysis (Table 2). No systematic 
reviews were identified. All investigations were presented as 
original research papers published in peer-reviewed indexed 
journals. While only one study investigated the impact of 
pharmacist intervention in inpatient sites, the remaining 
investigations were conducted in either community pharma-
cies or primary care pharmacy settings.
All studies involved patients with depression and 
pharmacist interventions. In toto, 1904 patients and 
136 pharmacists participated in the selected studies, which 
had short follow-up; only two studies continued up to 
12 months.17,18 Moreover, in all of these trials neither patients 
nor pharmacists were blinded, which led to a decrease in 
the quality of studies, ie, a score less than 5 in terms of the 
Jadad scale.
The majority of the studies involved fewer than seven 
pharmacists, and four papers described interventions by just 
two pharmacists.13,15,18,29 Although involving small numbers 
of pharmacists may make for good internal consistency, the 
results obtained may not be generalizable to the outcomes of 
services provided by the wider pharmacy profession. Overall, 
the studies involved a pharmacist–patient ratio of 1:14, which 
is not commensurate with clinical practice.
Methodological quality ranged from 2 to 5 on the Jadad 
scale, and nine of the studies scored 3 or more which 
represents high-quality studies with adequate randomiza-
tion, flow, and fate of all patients in the trial known; in case 
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1
0
% of no data, the reasons were stated. The most commonly 
absent item was an adequate description of concealment 
of allocation. Only two studies18,22 – which had a score 
of less than 3 on the Jadad scale and hence reflected 
poor-quality research – reasonably reported no change in 
adherence rate.
Adherence to antidepressants
Researchers utilized numerous measurements to measure 
the change of medication adherence in these papers: patient 
self-reports (n = 6), pill counts (n = 3), prescription claims 
(n = 2), and an electronic pill container (n = 1). This led 
to the widely mixed results observed in these papers. All 
the investigators during the study included one method to 
measure the change in adherence either subjectively or 
objectively.
The impact of interventions by pharmacists on medica-
tion adherence as outlined in the studies in this review is 
summarized in Table 3. Seven investigations reported an 
improvement in patients’ adherence and two studies reported 
no significant change in patients’ adherence between control 
and tested groups; only three studies reported no change in 
adherence rate. All the latter three studies were conducted 
in an outpatient setting with a relatively small sample size 
reflecting an underpowered study.18,22,24 Notably, two of 
the studies18,19 that failed to show differences in effect on 
patients’ adherence had multiple interventions, ie, three or 
more different types of intervention.
Impact of intervention on patients’ 
reported outcomes and depression 
severity
According to this systematic review, the majority of the 
papers monitored psychological dimensions such as depres-
sive symptoms, mood, satisfaction, knowledge, and others. 
Eight studies measured depressive symptoms and six of 
them reported no statistical difference in improvement in 
depressive symptoms between the pharmacist intervention 
group and the control group. Only two studies13,24 reported 
improvement in depressive symptoms at various levels 
using various measures. Only four studies13,14,16,21 reported 
an improvement in patients’ satisfaction with the treatment 
and three studies reported a change in patients drug knowl-
edge14,19,21 after pharmacist intervention. The improvement 
in depression severity and patients’ reported outcomes are 
summarized in Table 4, with an in-depth analysis of these 
studies shown in Table 5.
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s
 
s
a
t
i
s
fi
e
d
 
w
i
t
h
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
 
t
r
e
a
t
m
e
n
t
 
a
t
 
b
a
s
e
l
i
n
e
2
.
 
 
P
h
a
r
m
a
c
i
s
t
 
m
o
n
i
t
o
r
i
n
g
 
p
o
s
i
t
i
v
e
l
y
 
i
n
fl
u
e
n
c
e
d
 
a
d
h
e
r
e
n
c
e
 
 
f
o
r
 
p
a
t
i
e
n
t
s
 
t
a
k
i
n
g
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
s
 
f
o
r
 
t
h
e
 
fi
r
s
t
 
t
i
m
e
F
i
n
l
e
y
1
5
I
n
t
a
k
e
 
a
n
d
 
f
o
l
l
o
w
-
u
p
 
i
n
t
e
r
v
i
e
w
s
 
(
t
h
r
e
e
 
c
l
i
n
i
c
 
v
i
s
i
t
s
 
 
a
n
d
 
fi
v
e
 
p
h
o
n
e
 
c
a
l
l
s
)
;
 
m
e
d
i
c
a
l
 
h
i
s
t
o
r
y
 
r
e
v
i
e
w
;
 
d
r
u
g
 
p
r
e
s
c
r
i
b
i
n
g
 
a
n
d
 
d
o
s
e
 
c
h
a
n
g
e
s
 
u
n
d
e
r
 
p
r
o
t
o
c
o
l
;
 
 
d
r
u
g
 
i
n
f
o
r
m
a
t
i
o
n
 
c
o
u
n
s
e
l
i
n
g
P
a
t
i
e
n
t
 
s
a
t
i
s
f
a
c
t
i
o
n
;
 
c
l
i
n
i
c
 
v
i
s
i
t
 
f
r
e
q
u
e
n
c
y
;
 
R
e
s
o
u
r
c
e
 
u
t
i
l
i
z
a
t
i
o
n
1
.
 
C
l
i
n
i
c
 
v
i
s
i
t
 
d
e
c
l
i
n
e
 
w
a
s
 
d
i
f
f
e
r
e
n
t
 
(
3
9
%
 
v
s
 
1
2
%
)
 
2
.
 
P
a
t
i
e
n
t
s
 
w
e
r
e
 
m
o
r
e
 
s
a
t
i
s
fi
e
d
 
i
n
 
i
n
t
e
r
v
e
n
t
i
o
n
 
g
r
o
u
p
F
i
n
l
e
y
1
6
D
r
u
g
 
m
o
n
i
t
o
r
i
n
g
;
 
p
a
t
i
e
n
t
 
e
d
u
c
a
t
i
o
n
;
 
r
o
u
t
i
n
e
 
f
o
l
l
o
w
-
u
p
 
 
e
x
t
e
n
s
i
v
e
 
p
h
o
n
e
 
c
a
l
l
s
 
a
t
 
w
e
e
k
s
 
1
,
 
2
,
 
4
,
 
1
0
,
 
a
n
d
 
1
6
;
 
 
d
r
u
g
 
p
r
e
s
c
r
i
b
i
n
g
 
a
n
d
 
m
e
d
i
c
a
t
i
o
n
 
c
h
a
n
g
e
 
u
n
d
e
r
 
p
r
o
t
o
c
o
l
P
a
t
i
e
n
t
 
s
a
t
i
s
f
a
c
t
i
o
n
;
 
c
l
i
n
i
c
 
v
i
s
i
t
 
f
r
e
q
u
e
n
c
y
;
 
r
e
s
o
u
r
c
e
 
u
t
i
l
i
z
a
t
i
o
n
1
.
 
I
n
t
e
r
v
e
n
t
i
o
n
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
m
o
r
e
 
s
a
t
i
s
fi
e
d
 
w
i
t
h
 
t
r
e
a
t
m
e
n
t
 
2
.
 
C
l
i
n
i
c
 
v
i
s
i
t
s
 
d
e
c
l
i
n
e
d
 
b
y
 
1
3
%
 
(
1
5
%
 
v
s
 
2
%
)
 
3
.
 
D
r
u
g
 
c
o
s
t
 
o
f
 
i
n
t
e
r
v
e
n
t
i
o
n
 
p
a
t
i
e
n
t
s
 
i
n
c
r
e
a
s
e
d
 
b
y
 
4
2
%
 
4
.
 
 
N
o
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
i
m
p
r
o
v
e
m
e
n
t
 
o
f
 
d
e
p
r
e
s
s
i
v
e
 
s
y
m
p
t
o
m
s
A
d
l
e
r
1
7
C
o
n
t
a
c
t
i
n
g
 
p
a
t
i
e
n
t
s
 
n
i
n
e
 
t
i
m
e
s
 
o
v
e
r
 
t
h
e
 
1
8
-
m
o
n
t
h
 
s
t
u
d
y
;
 
r
e
v
i
e
w
i
n
g
 
m
e
d
i
c
a
t
i
o
n
 
h
i
s
t
o
r
y
,
 
d
r
u
g
 
s
i
d
e
 
e
f
f
e
c
t
s
 
a
n
d
 
e
f
fi
c
a
c
y
;
 
 
a
s
s
i
s
t
i
n
g
 
d
r
u
g
 
c
h
o
i
c
e
,
 
d
o
s
e
,
 
a
n
d
 
r
e
g
i
m
e
n
;
 
p
r
o
v
i
d
i
n
g
 
s
o
c
i
a
l
 
 
s
u
p
p
o
r
t
;
 
e
d
u
c
a
t
i
n
g
 
p
a
t
i
e
n
t
s
 
t
o
 
m
a
i
n
t
a
i
n
 
m
e
d
i
c
a
t
i
o
n
D
e
p
r
e
s
s
i
o
n
 
s
e
v
e
r
i
t
y
1
.
 
 
F
o
r
 
p
a
t
i
e
n
t
s
 
u
s
i
n
g
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
s
 
a
t
 
s
t
u
d
y
 
e
n
t
r
y
,
 
n
o
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
 
u
s
e
 
w
e
r
e
 
o
b
s
e
r
v
e
d
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
 
a
t
 
3
 
o
r
 
6
 
m
o
n
t
h
s
2
.
 
 
F
o
r
 
p
a
t
i
e
n
t
s
 
n
o
t
 
o
n
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
s
 
a
t
 
s
t
u
d
y
 
e
n
t
r
y
,
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
 
u
s
e
 
r
a
t
e
 
w
a
s
 
h
i
g
h
e
r
 
i
n
 
i
n
t
e
r
v
e
n
t
i
o
n
 
 
p
a
t
i
e
n
t
s
 
a
t
 
b
o
t
h
 
3
 
m
o
n
t
h
s
 
a
n
d
 
6
 
m
o
n
t
h
s
C
a
p
o
c
c
i
a
1
8
P
e
r
f
o
r
m
i
n
g
 
p
a
t
i
e
n
t
 
f
o
l
l
o
w
-
u
p
 
b
y
 
p
h
o
n
e
 
I
n
t
e
r
v
i
e
w
i
n
g
 
p
a
t
i
e
n
t
s
 
 
t
w
o
 
t
i
m
e
s
 
d
u
r
i
n
g
 
c
l
i
n
i
c
 
v
i
s
i
t
s
;
 
p
a
t
i
e
n
t
 
c
o
n
t
a
c
t
 
d
u
r
i
n
g
 
c
l
i
n
i
c
 
v
i
s
i
t
s
 
 
(
w
e
e
k
s
 
4
 
a
n
d
 
1
2
)
;
 
m
o
n
i
t
o
r
i
n
g
 
d
r
u
g
 
t
r
e
a
t
m
e
n
t
 
(
t
i
m
e
 
d
r
u
g
s
 
t
a
k
e
n
,
 
 
c
h
a
n
g
e
 
o
f
 
d
r
u
g
s
 
a
n
d
 
o
t
h
e
r
 
t
r
e
a
t
m
e
n
t
)
;
 
e
d
u
c
a
t
i
n
g
 
p
a
t
i
e
n
t
s
 
o
n
 
s
i
d
e
 
 
e
f
f
e
c
t
s
;
 
p
r
o
v
i
d
i
n
g
 
d
r
u
g
 
r
e
fi
l
l
s
 
a
n
d
 
m
e
d
i
c
a
t
i
o
n
 
d
o
s
e
 
a
d
j
u
s
t
m
e
n
t
D
e
p
r
e
s
s
i
v
e
 
s
y
m
p
t
o
m
s
;
 
p
a
t
i
e
n
t
 
s
a
t
i
s
f
a
c
t
i
o
n
,
 
 
a
n
d
 
c
l
i
n
i
c
a
l
 
v
i
s
i
t
s
1
.
 
N
o
 
o
v
e
r
a
l
l
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
s
a
t
i
s
f
a
c
t
i
o
n
 
w
i
t
h
 
d
e
p
r
e
s
s
i
o
n
 
c
a
r
e
 
2
.
 
 
N
o
 
o
v
e
r
a
l
l
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
i
m
p
r
o
v
e
m
e
n
t
 
o
f
 
d
e
p
r
e
s
s
i
o
n
 
s
y
m
p
t
o
m
s
 
w
a
s
 
o
b
s
e
r
v
e
d
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
3
.
 
 
N
o
 
d
i
f
f
e
r
e
n
c
e
 
b
e
t
w
e
e
n
 
t
h
e
 
t
w
o
 
g
r
o
u
p
s
 
i
n
 
n
u
m
b
e
r
 
o
f
 
v
i
s
i
t
s
 
t
o
 
a
l
l
 
h
e
a
l
t
h
 
c
a
r
e
 
p
r
o
v
i
d
e
r
s
 
w
a
s
 
o
b
s
e
r
v
e
d
R
i
c
k
l
e
s
1
9
C
o
n
d
u
c
t
i
n
g
 
t
h
r
e
e
 
m
o
n
t
h
l
y
 
p
h
o
n
e
 
c
a
l
l
s
 
t
o
 
p
a
t
i
e
n
t
s
:
 
d
u
r
i
n
g
 
fi
r
s
t
 
 
c
a
l
l
,
 
a
s
s
e
s
s
i
n
g
 
p
a
t
i
e
n
t
’
s
 
d
r
u
g
 
k
n
o
w
l
e
d
g
e
 
a
n
d
 
b
e
l
i
e
f
,
 
a
d
v
e
r
s
e
 
e
f
f
e
c
t
s
,
 
d
r
u
g
 
u
s
e
 
s
t
a
t
u
s
,
 
t
r
e
a
t
m
e
n
t
 
g
o
a
l
s
,
 
a
n
d
 
s
e
l
f
-
r
a
t
e
d
 
d
e
p
r
e
s
s
i
o
n
 
s
e
v
e
r
i
t
y
;
 
f
o
l
l
o
w
-
u
p
 
d
u
r
i
n
g
 
s
e
c
o
n
d
 
a
n
d
 
t
h
i
r
d
 
c
a
l
l
.
F
r
e
q
u
e
n
c
y
 
o
f
 
f
e
e
d
b
a
c
k
 
t
o
 
p
h
a
r
m
a
c
i
s
t
;
 
d
e
p
r
e
s
s
i
v
e
 
s
y
m
p
t
o
m
s
;
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
 
k
n
o
w
l
e
d
g
e
 
a
n
d
 
 
d
r
u
g
 
b
e
l
i
e
f
1
.
 
N
o
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
fi
c
a
n
t
 
i
m
p
a
c
t
 
o
n
 
d
e
p
r
e
s
s
i
v
e
 
s
y
m
p
t
o
m
s
 
2
.
 
D
e
p
r
e
s
s
i
v
e
 
s
y
m
p
t
o
m
s
 
i
m
p
r
o
v
e
d
 
i
n
 
b
o
t
h
 
g
r
o
u
p
s
 
3
.
 
 
I
n
t
e
r
v
e
n
t
i
o
n
 
p
a
t
i
e
n
t
s
 
h
a
d
 
h
i
g
h
e
r
 
s
c
o
r
e
s
 
i
n
 
d
r
u
g
 
k
n
o
w
l
e
d
g
e
 
a
n
d
 
b
e
l
i
e
f
 
(
7
5
%
 
v
s
 
4
8
%
)
B
r
o
o
k
2
0
O
f
f
e
r
e
d
 
t
h
r
e
e
 
p
h
o
n
e
 
c
a
l
l
s
 
(
1
0
–
2
0
 
m
i
n
u
t
e
s
)
;
 
P
r
o
v
i
d
e
d
 
a
 
t
a
k
e
-
h
o
m
e
 
v
i
d
e
o
 
e
m
p
h
a
s
i
z
i
n
g
 
m
e
d
i
c
a
t
i
o
n
 
a
d
h
e
r
e
n
c
e
;
 
d
o
c
u
m
e
n
t
e
d
 
n
u
m
b
e
r
 
o
f
 
p
i
l
l
s
 
a
n
d
 
r
e
fi
l
l
 
d
a
t
e
D
e
p
r
e
s
s
i
v
e
 
s
y
m
p
t
o
m
s
N
o
 
i
m
p
r
o
v
e
m
e
n
t
 
i
n
 
d
e
p
r
e
s
s
i
v
e
 
s
y
m
p
t
o
m
s
 
w
a
s
 
o
b
s
e
r
v
e
d
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A
l
-
S
a
f
f
a
r
2
1
P
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
d
 
a
 
p
a
t
i
e
n
t
 
i
n
f
o
r
m
a
t
i
o
n
 
l
e
a
fl
e
t
 
w
r
i
t
t
e
n
 
i
n
 
 
A
r
a
b
i
c
 
w
i
t
h
 
c
o
u
n
s
e
l
i
n
g
I
n
t
e
r
v
i
e
w
 
q
u
e
s
t
i
o
n
n
a
i
r
e
s
1
.
 
 
P
a
t
i
e
n
t
s
 
i
n
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
h
a
d
 
a
n
 
i
m
p
r
o
v
e
d
 
k
n
o
w
l
e
d
g
e
 
o
f
 
t
h
e
 
r
a
t
i
o
n
a
l
e
 
o
f
 
t
r
e
a
t
m
e
n
t
 
2
.
 
 
C
l
i
n
i
c
 
a
t
t
e
n
d
a
n
c
e
 
w
a
s
 
m
o
r
e
 
l
i
k
e
l
y
 
w
h
e
n
 
p
a
t
i
e
n
t
s
 
h
a
d
 
r
e
c
e
i
v
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
3
.
 
 
P
r
e
e
x
i
s
t
i
n
g
 
p
a
t
i
e
n
t
 
a
t
t
i
t
u
d
e
s
 
t
o
 
t
h
e
r
a
p
y
 
a
n
d
 
t
h
e
 
o
c
c
u
r
r
e
n
c
e
 
o
f
 
s
i
d
e
 
e
f
f
e
c
t
s
 
w
e
r
e
 
n
o
t
 
d
e
t
e
r
m
i
n
a
n
t
s
 
 
o
f
 
a
d
h
e
r
e
n
c
e
C
r
o
c
k
e
t
t
2
2
P
h
a
r
m
a
c
i
s
t
s
 
w
e
r
e
 
g
i
v
e
n
 
v
i
d
e
o
-
c
o
n
f
e
r
e
n
c
e
 
t
r
a
i
n
i
n
g
 
o
n
 
t
h
e
 
n
a
t
u
r
e
 
 
a
n
d
 
m
a
n
a
g
e
m
e
n
t
 
o
f
 
d
e
p
r
e
s
s
i
o
n
 
b
y
 
a
 
p
s
y
c
h
i
a
t
r
i
s
t
,
 
p
s
y
c
h
o
l
o
g
i
s
t
 
 
a
n
d
 
g
e
n
e
r
a
l
 
p
r
a
c
t
i
t
i
o
n
e
r
 
a
n
d
 
a
s
k
e
d
 
t
o
 
d
i
s
p
e
n
s
e
 
m
e
d
i
c
a
t
i
o
n
 
 
w
i
t
h
 
e
x
t
r
a
 
a
d
v
i
c
e
 
a
n
d
 
s
u
p
p
o
r
t
K
1
0
 
a
n
d
 
D
r
u
g
 
A
t
t
i
t
u
d
e
 
I
n
d
e
x
1
.
 
 
B
o
t
h
 
g
r
o
u
p
s
 
h
a
d
 
i
m
p
r
o
v
e
d
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
i
n
 
w
e
l
l
-
b
e
i
n
g
 
(
a
 
r
e
d
u
c
t
i
o
n
 
K
1
0
 
s
c
o
r
e
 
o
f
 
4
 
(
c
o
n
t
r
o
l
)
 
v
e
r
s
u
s
 
4
.
7
 
(
i
n
t
e
r
v
e
n
t
i
o
n
)
)
2
.
 
 
N
o
 
s
i
g
n
i
fi
c
a
n
t
 
c
h
a
n
g
e
 
w
a
s
 
f
o
u
n
d
 
i
n
 
a
t
t
i
t
u
d
e
 
t
o
 
d
r
u
g
 
t
r
e
a
t
m
e
n
t
 
o
n
c
e
 
b
a
s
e
l
i
n
e
 
s
c
o
r
e
s
 
w
e
r
e
 
c
o
n
t
r
o
l
l
e
d
 
f
o
r
R
i
c
k
l
e
s
2
3
T
h
r
e
e
 
m
o
n
t
h
l
y
 
t
e
l
e
p
h
o
n
e
 
c
a
l
l
s
 
f
r
o
m
 
p
h
a
r
m
a
c
i
s
t
s
 
p
r
o
v
i
d
i
n
g
 
 
s
t
r
u
c
t
u
r
e
d
 
e
d
u
c
a
t
i
o
n
 
a
n
d
 
m
o
n
i
t
o
r
i
n
g
F
r
e
q
u
e
n
c
y
 
o
f
 
p
a
t
i
e
n
t
 
f
e
e
d
b
a
c
k
 
t
o
 
p
h
a
r
m
a
c
i
s
t
s
,
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
 
k
n
o
w
l
e
d
g
e
,
 
d
e
p
r
e
s
s
i
v
e
 
s
y
m
p
t
o
m
s
S
i
g
n
i
fi
c
a
n
t
l
y
 
m
o
r
e
 
f
e
e
d
b
a
c
k
 
t
o
 
p
h
a
r
m
a
c
i
s
t
s
 
r
e
g
a
r
d
i
n
g
 
d
i
f
f
e
r
e
n
t
 
a
s
p
e
c
t
s
 
o
f
 
t
h
e
i
r
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
 
t
h
e
r
a
p
y
B
o
s
m
a
n
s
2
4
O
f
f
e
r
e
d
 
t
h
r
e
e
 
e
d
u
c
a
t
i
o
n
 
a
n
d
 
c
o
a
c
h
i
n
g
 
p
r
o
g
r
a
m
s
 
a
n
d
 
a
 
 
t
a
k
e
-
h
o
m
e
 
v
i
d
e
o
 
r
e
v
i
e
w
i
n
g
 
i
m
p
o
r
t
a
n
t
 
f
a
c
t
s
 
o
n
 
d
e
p
r
e
s
s
i
o
n
 
 
a
n
d
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
 
t
r
e
a
t
m
e
n
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Types of pharmacist intervention
Five different types of pharmacist intervention were imple-
mented in studies included in this review, which were as 
follows: (1) educating and counseling patients about the 
importance of adherence, explaining the side effects of 
medications and reviewing regimens; (2) monitoring drugs 
and following up drug reactions; (3) prescribing drug 
and dose changes to simplify regimens under protocol; 
(4) following up patients by phone calls and providing 
all information and response to patients enquiries, and 
(5) educating patients by providing a take-home video 
emphasizing the importance of medication adherence.13–24 
The most common intervention strategy that pharmacists 
utilized was a combination of drug monitoring, drug 
counseling, and patient education. Four studies reported 
that pharmacists were authorized to prescribe medications 
and change doses under the supervision of psychiatrists 
or physicians.
A telephone call or a reminder was found to be an 
effective approach to improve medication adherence 
(Table 6). Five of six studies that included telephone 
  contact with patients in the intervention reported a sub-
stantial improvement in medication adherence. The results 
of the only study that reported no significant change in 
adherence18 were probably due to a high adherence rate 
in the control group; a low ratio of pharmacists’ contact 
with patients that is one contact every 3 months, and an 
underpowered sample size (n = 74). However, the strategy 
of telephone support is limited in the extent to which it can 
be generalized for clinical practices because of time and 
cost considerations. Telephone contact can also be a barrier 
to clear communication and thus may affect the patients’ 
level of understanding.
Five studies assessed the impact of pharmacist interven-
tion by providing patient education and monitoring.13,16–19 
Four of the five studies demonstrated that involvement 
of the pharmacist was associated with a significant 
improvement in medication adherence.13,16,17,19 Again, it was 
the study reported by Capoccia and associates18 that found 
no significant change in adherence, which can be related 
to the aforementioned factors. The general findings from 
previous literature intervention studies and this review 
have shown that psychoeducation is an effective means of 
enhancing treatment adherence by offering structured and 
detailed information to patients about their treatments.3,30–32 
This positive outcome may also be related to patients’ 
ever-changing belief systems about their antidepressant 
medications.33
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Table 5 Detailed information about studies included in this review, 2000–2010
Study Type of publication Year of  
publication
Year study conducted Methodology Study  
location
Setting Study  
participants
Sample  
size
Brief description of study aims
Canales13 Paper published in indexed American 
Journal of Health-System Pharmacy
2001 October 1996 to  
December 1997
Carried out in two phases;  
control and experimental groups
Texas,  
USA
Inpatient 2 93 To determine the effects of a psychiatric pharmacist on clinical 
outcomes of acute care psychiatric inpatients and to monitor 
hospitalization costs
Bultman14 Paper published in indexed Journal of  
the American Pharmacists Association
2002 November 1995 to  
July 1996
Systematic, random sample of 
pharmacies and field study, patients 
were interviewed two times during 
the study
wisconsin,  
USA
Community pharmacy 23 100 To examine the effects of pharmacist monitoring on patient 
satisfaction and adherence to antidepressant medication therapy
Finley15 Paper published in indexed American 
Journal of Health-System Pharmacy
2002 July 1999 to June 2000,  
10 months enrolment phase
Pharmacist follows up the patients 
through a combination of scheduled 
office visits and telephone calls. 
working closely with psychiatric 
liaisons
California,  
USA
Primary care pharmacy 2 220 To examine effort to improve patient adherence to antidepressant 
drug therapy and outcomes
Finley16 Paper published in indexed 
Pharmacotherapy
2003 Study conducted for 15 months,  
9 months enrolment phase
A randomized controlled trial, 
compared the outcomes of 
intervention in care model with 
subjects receiving usual care
California,  
USA
Primary care pharmacy 2 150 To measure the effects of a collaborative care model that emphasized 
the role of clinical pharmacists in providing drug therapy management 
and treatment follow-up to patients with depression
Adler17 Paper published in indexed General  
Hospital Psychiatry
2004 1998 to 2000 A randomized clinical trial of 
a pharmacist intervention for 
depressed patients, report 
antidepressant use and depression 
severity outcomes
Massachusetts,  
USA
Primary care pharmacy 5 533 To evaluate outcomes of a pharmacist intervention for depressed 
patients in primary care
Capoccia18 Paper published in indexed American 
Journal of Health-System Pharmacy
2004 Study conducted for 16 months,  
November 1999 to March 2001
Patients were randomized to 
enhanced care or usual care groups, 
for 1 year
washington,  
USA
Primary care pharmacy 2 74 To evaluate the impact of pharmacist’s interventions in collaborative 
care to improve the care of, and outcomes for, patients with 
depression, to test the effectiveness of pharmacist interventions in 
collaboration models
Rickles19 Paper published in indexed Journal of the 
American Pharmacists Association
2005 October 1, 2001 to  
September 30, 2002
Randomized, controlled, unblended, 
mixed experimental design
wisconsin,  
USA
Community pharmacy 14 63 To explore the impact of telephone-based education and monitoring 
by community pharmacists on multiple outcomes of pharmacist–
patient collaboration
Brook20 Paper published in indexed Journal of 
Psychiatric Services
2005 April 2000 to April 2001 Randomized controlled trial with 
6-month follow-up
The Netherlands Community pharmacy 19 147 To improve adherence to antidepressant regimens through a 
pharmacist intervention
Al-Saffar21 Paper published in indexed Journal of 
International Journal of Pharmacy Practice
2005 Study conducted for 18 months,  
1999 to 2001
Randomized into a control  
and two treatment groups. 
Treatment groups additionally 
received a patient information leaflet
Kuwait Outpatient 7 270 To assess the acceptability and effectiveness of two educational 
initiatives on patterns of antidepressant medication use in depressed 
Kuwaiti patients
Crockett22 Paper published in indexed The  
Australian Journal of Rural Health
2006 Parallel-groups design with a control 
and intervention group
New South wales,  
Australia
Community pharmacy 32 106 Documentation and evaluation of patient outcomes into the role of 
rural community pharmacists in the management of depression
Rickles23 Paper published in indexed Journal of  
the American Pharmacists Association
2006 October 1, 2001 to  
September 30, 2002
Randomized, controlled, 
experimental design
wisconsin,  
USA
Community pharmacy 14 60 To determine whether telephone follow-up can influence the nature 
and extent to which antidepressant users provide feedback to 
pharmacists, whether patient characteristics are associated with the 
extent of patient feedback, how patient feedback affects subsequent 
outcomes after controlling for patient characteristics
Bosmans24 Paper published in indexed Journal of 
PharmacoEconomics
2007 April 2000 to April 2001 An economic evaluation performed 
alongside a 6-month randomized 
controlled trial
The Netherlands Community pharmacy 19 88 To evaluate the cost effectiveness of a pharmacy-based intervention 
to improve adherence to antidepressant therapy in adult patients 
receiving treatment in primary care
Discussion
The challenge of evaluating complex and multifactorial 
pharmacist interventions with a combination of different 
adherence strategies has resulted in mixed outcomes and 
made it difficult to identify the most effective role that phar-
macists may assume. In addition, heterogeneity in pharmacist 
interventions, treatment settings, patient populations, and 
measured outcomes is apparently large enough to discourage 
a meta-analysis of these findings.
This systematic review addressed an important role of 
pharmacists in providing pharmaceutical care to patients 
with depression. This critical narrative review revealed a 
positive effect of pharmacist interventions on antidepressant 
medication adherence by patients. The findings of this study 
are consistent with those of other researchers.34 In addition 
to revealing a positive effect of pharmacists’ intervention; 
this review also substantiated claims of improved medication 
adherence among depressed people who were treated by 
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antidepressant medications prescribed by community mental 
health teams in Australia.34
There are some limitations in this research. Firstly, though 
a positive outcome in patient adherence to antidepressant 
medication was identified, it is unclear whether or not this 
will result in an improvement in depressive symptoms. 
However, previous studies have reported a positive associa-
tion between improved antidepressant medication adherence 
and depressive symptoms, attributed to substantial changes 
in adherence to antidepressant medications.35 Secondly, the 
randomized controlled trials included had different method-
ological approaches, such as the pharmacy settings in terms 
of outpatient and inpatient pharmacy, type of diagnostic 
measures, adherence measures, and types of intervention 
performed. The different methodologies applied in the 
reviewed studies make the interpretation of results difficult. 
Thirdly, no study measured the relation between the change 
in adherence and relapse of depression because most studies 
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were of less than 7 months’ duration. It has been suggested 
that in order to assess the effectiveness of an intervention 
on relapse of depression, the intervention and follow-up 
duration should be extended to at least 2 years.12 Largely, 
a 6-month follow-up period is a short time when referring 
to antidepressant treatment given to patients with multiple 
relapses of depression. This period needs to be extended to 
at least 6 months when remission of an episode of depression 
is expected. However, evidently dropouts occur mostly at the 
beginning of treatment with antidepressant medications. In 
some trials, the 2-month follow-up period did not alter the 
results including effect sizes.22
Fourthly, the included studies used different medication 
adherence measures as there is no cornerstone measurement 
for medication adherence. The objective (pill counts, electronic 
monitoring, and monitoring blood plasma concentration) 
versus subjective (self-administered questionnaires, self-
reports, and physicians evaluation reports) medication 
adherence measurements tend to cause varied results 
in medication adherence studies. However, limiting the 
measurement to just one method increases the possibility 
of imprecise measurement of changes in adherence, while 
using two methods will overcome the disadvantage of each 
method alone. Only Al-Saffar and colleagues21 utilized 
two methods: tablet counting and patient self-report. For 
instance, Velligan et al36 reported that the data from objective 
measurements to oral antipsychotic medications were 
strongly correlated (r[k] = 0.61) but subjective measurements 
were weakly correlated with objective measurements, when 
adherence scores were examined by rank-order correlations 
(r[k] = 0.18–0.32). Blood plasma concentrations, an objective 
measurement, were not correlated with any other measures 
of adherence (kappa # 20). They also found that the data 
from subjective measurement reports were best correlated 
with clinical state, which can be reliably utilized in daily 
clinical practices.
Fifthly, most of the included articles were published in 
pharmacy journals, ie, nine out of 12; it is quite possible that 
a publication bias influenced this trend. The majority of the 
studies involved compared the effectiveness of intervention 
between pharmacists’ intervention group and usual care 
control group. However, none of these studies directly com-
pared the effectiveness of intervention between pharmacists 
and other healthcare providers. Adverse drug side effects 
was cited as the leading cause of early discontinuation of 
medication and non-adherence to treatment: none of these 
studies indicated pharmacist intervention to manage these 
side effects.
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Finally, in spite of these limitations, this study is, to the 
best of our knowledge, the first published systematic review 
of pharmacist interventions in patients with depression. Our 
review indicates that pharmacist interventions can improve 
patient adherence to antidepressant medications and also 
highlights the role of pharmacists in psychiatric pharmaceuti-
cal care services. These data show that patient counseling and 
treatment monitoring conducted by pharmacists can improve 
adherence to antidepressant medication.
Conclusion
This systematic review of the literature highlighted the 
expanded roles of pharmacists, especially their interventions 
in the management of patients with depression in particular 
adherence to drug regimen. Notably, the data showed that 
patient counseling and treatment monitoring conducted 
by pharmacists can improve adherence to antidepressant 
medications. Pharmacist-conducted medication reviews and 
resulting recommendations to optimize medication use by 
patients with depression may reduce the complexity of the 
medication regimen and adherence. The available published 
evidence-based data tend to support the continued expansion 
of the pharmacist’s role in the care of patients with depression 
and adherence to the treatment. Further studies are needed to 
assess the clinical outcomes of innovative pharmacist inter-
ventions based on theories that can explain the outcome and 
mechanisms of change with regard to patient adherence to 
medication. In summary, evidence from the studies reviewed 
strongly support the role of pharmacists in providing differ-
ent types of interventions to improve medication adherence 
to antidepressant treatment by patients with depression in 
different settings.
Special note
In major psychiatric treatment settings in the Kingdom of 
Saudi Arabia, pharmacist clinics have been established to 
provide counseling, review of prescribed medications, and 
collaborative management of the adverse effects of psy-
chotropic drugs in outpatient settings. In addition, clinical 
pharmacists are important active players in multidisciplinary 
clinical teams that undertake regular rounds of inpatients and 
discuss different issues, including medications. Pharmacists 
contribute to the safe prescription and dispensing of drugs 
to health consumers, coupled with brief counseling focusing 
on adherence to treatment and its benefits. There is no data-
base regarding their multiple roles and their effectiveness in 
clinical pharmacy services. Therefore, it would be timely to 
conduct studies in the Kingdom of Saudi Arabia that focus 
on pharmacist interventions and how to enhance medication 
adherence in the psychiatric population in general but in 
particular in patients with depression.
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